Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BostonGene logo — Transforming Cancer Care: From Treating a Diagnosis to Treat...

BostonGene

Transforming Cancer Care: From Treating a Diagnosis to Treating the Person

Founded 2015 United States Waltham, United States 436 employees Series B Total: $200.00M Analytics, Health Care +1

General Information

Company Name BostonGene
Founded Year 2015
Location United States Waltham, United States
Founders / Decision Makers
Team member
Employees 436
Industries Analytics, Health Care, Clean Energy
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with BostonGene. To contact BostonGene, visit bostongene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BostonGene compare?

A PDF of BostonGene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BostonGene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BostonGene

BostonGene is a transformative startup with a slogan of "Transforming Cancer Care: From Treating a Diagnosis to Treating the Person." Founded in 2015 and based in the United States, the company is focused on providing AI-integrated molecular analytics and biomarker discovery for precision matching of therapies in cancer and immune-related diseases. BostonGene operates under a concierge-service model, offering customized client solutions utilizing a multi-omic approach prioritized for real-world impact. The startup aims to optimize standard-of-care therapies, accelerate research, and deliver cost-effective, measurable data-driven results. In April 2022, BostonGene secured a significant $150.00M Series B investment from notable investors including Japan Industrial Partners, NEC Corporation, and Impact Investment Capital. The company's tests provide personalized insights into each patient's unique disease profile, offering an in-depth analysis of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended treatment options. BostonGene's comprehensive analyses generate a personalized roadmap for therapeutic decision-making for each patient, aiming to revolutionize cancer care and improve patient outcomes. With its focus on precision medicine and impactful results, the company stands out in the Analytics and Health Care industries, showcasing the potential for successful disruption and innovation in the field of cancer treatment and beyond.

Business keywords: Precision Medicine, Cancer Care, Biomarker Discovery, AI-Integrated Analytics, Personalized Therapy, Immunooncology, Bioinformatics, Genomics, Medical Technology, Therapeutic Decision-Making, Concierge-Service Model

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $150.00M 3
Japan Industrial Partners
Japan Industrial Partners, NEC Corporation +1
06 Apr 2022
Series A $50.00M 1
NEC Corporation
25 Apr 2019

BostonGene Alternatives & Competitors

BostonGene vs
ACT Genomics
ACT Genomics Taiwan

Make Personalized Medicine Accessible To All.

Venture round
121 employees
Biotechnology, Health Care
BostonGene vs
CureMatch, Inc.
CureMatch, Inc. United States

AI-based Precision Medicine Decision Support for Oncology

Venture round
26 employees
Analytics, Health Care
BostonGene vs
Elucidata
Elucidata United States

The AI Partner Fueling
40+ FDA-Track Drugs

Series A
179 employees
AI, Analytics

FAQ About BostonGene

Transforming Cancer Care: From Treating a Diagnosis to Treating the Person
BostonGene was founded in 2015.
BostonGene is headquartered in Waltham, United States.
BostonGene operates in Analytics, Health Care and Clean Energy. Its work centres on Precision Medicine, Cancer Care, Biomarker Discovery and AI-Integrated Analytics.
BostonGene has approximately 436 employees.
BostonGene has completed 2 funding rounds, raising a total of $200.00M. The latest funding stage is Series B.
Top alternatives and competitors to BostonGene include ACT Genomics, CureMatch, Inc., Elucidata, Helix, Hurdle. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BostonGene and ACT Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BostonGene, https://bouncewatch.com/company/bostongene, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes